Global Fortune 500 Pharmaceutical

 

Company Information

CEO	Wang Xiangming
Sector	Health Care
Industry	Pharmaceuticals
HQ Location	Hong Kong
Website	https://www.crc.com.hk
Years on Global 500 List	10
Employees	421,274

Key Financials (Last Fiscal Year)

($ Millions)	% change
Revenues ($M)	$91,986.00	11.9%
Profits ($M)	$3,474.60	10.2%
Assets ($M)	$209,651.50	-
Total Stockholder Equity ($M)	$28,198.80	-

Profit Ratios

Profit as % of Revenues	3.8%
Profits as % of Assets	1.7%
Profits as % of Stockholder Equity	12.3%

The 133-year-old health care conglomerate makes everything from Band-Aids and baby shampoo to contact lenses and hip implants, but its $40.7 billion pharmaceutical division is what drove the most revenue growth in 2018. The company’s cancer and immunology drugs sold especially well. J&J’s medical device division eked out sales growth despite divestitures, as did the company’s consumer business, which continues to see challenges in its recently relaunched baby care line. The company faces more than 13,000 lawsuits—and federal inquiries—over the safety of its talc-based baby powder. (J&J maintains the product is perfectly safe.)

​

Company Info

CEO	Alex Gorsky
CEO Title	Chairman & Chief Executive Officer
Sector	Health Care
Industry	Pharmaceuticals
HQ Location	New Brunswick, N.J.
Website	http://www.jnj.com
Years on Fortune 500 List	65
Employees	135,100

​

Key Financials (Last Fiscal Year)

($ Millions)	% change
Revenues ($M)	$81,581.00	6.7%
Profits ($M)	$15,297.00	1076.70%
Assets ($M)	$152,954.00	-
Total Stockholder Equity ($M)	$59,752.00	-

Profit Ratios

Profit as % of Revenues	18.8%
Profits as % of Assets	10%
Profits as % of Stockholder Equity	25.6%

Company Information

CEO	Severin Schwan
Sector	Health Care
Industry	Pharmaceuticals
HQ Location	Basel, Switzerland
Website	https://www.roche.com
Years on Global 500 List	25
Employees	94,442

Key Financials (Last Fiscal Year)

($ Millions)	% change
Revenues ($M)	$60,846.20	7.4%
Profits ($M)	$10,738.10	22.4%
Assets ($M)	$79,680.30	-
Total Stockholder Equity ($M)	$28,031.30	-

Profit Ratios

Profit as % of Revenues	17.6%
Profits as % of Assets	13.5%
Profits as % of Stockholder Equity	38.3%

Company Information

CEO	She Lulin
Sector	Health Care
Industry	Pharmaceuticals
HQ Location	Beijing
Website	https://www.sinopharm.com
Years on Global 500 List	7
Employees	128,600

Key Financials (Last Fiscal Year)

($ Millions)	% change
Revenues ($M)	$59,980.20	15.7%
Profits ($M)	$884.4	28.2%
Assets ($M)	$49,823.40	-
Total Stockholder Equity ($M)	$8,499.20	-

Profit Ratios

Profit as % of Revenues	1.5%
Profits as % of Assets	1.8%
Profits as % of Stockholder Equity	10.4%

In Ian Read’s final year as the company’s CEO, Pfizer managed to grow revenues by just 2% as it adjusted to greater competition to—and diminished sales of—Viagra and other drugs on which the company lost patent exclusivity in 2017. The pharmaceutical giant is now in the midst of a reorganization since announcing in the summer of 2018 that it would separate its business into three parts, one of which (its consumer health division) it plans to merge into a joint venture with GlaxoSmithKline. The moves are designed to position Pfizer for greater sales growth under new CEO Albert Bourla.

​

Company Information

CEO	Albert Bourla
Sector	Health Care
Industry	Pharmaceuticals
HQ Location	New York City
Website	https://www.pfizer.com
Years on Global 500 List	25
Employees	92,400

Key Financials (Last Fiscal Year)

($ Millions)	% change
Revenues ($M)	$53,647.00	2.1%
Profits ($M)	$11,153.00	-47.7%
Assets ($M)	$159,422.00	-
Total Stockholder Equity ($M)	$63,407.00	-

Profit Ratios

Profit as % of Revenues	20.8%
Profits as % of Assets	7%
Profits as % of Stockholder Equity	17.6%

Company Information

CEO	Vasant Narasimhan
Sector	Health Care
Industry	Pharmaceuticals
HQ Location	Basel, Switzerland
Website	https://www.novartis.com
Years on Global 500 List	25
Employees	125,161

Key Financials (Last Fiscal Year)

($ Millions)	% change
Revenues ($M)	$53,166.00	6%
Profits ($M)	$12,611.00	63.7%
Assets ($M)	$145,563.00	-
Total Stockholder Equity ($M)	$78,614.00	-

Profit Ratios

Profit as % of Revenues	23.7%
Profits as % of Assets	8.7%
Profits as % of Stockholder Equity	16%

Company Information

CEO	Werner Baumann
Sector	Health Care
Industry	Pharmaceuticals
HQ Location	Leverkusen, Germany
Website	https://www.bayer.com
Years on Global 500 List	25
Employees	116,998

Key Financials (Last Fiscal Year)

($ Millions)	% change
Revenues ($M)	$46,718.10	-10%
Profits ($M)	$2,000.40	-75.8%
Assets ($M)	$144,343.80	-
Total Stockholder Equity ($M)	$52,551.70	-

Profit Ratios

Profit as % of Revenues	4.3%
Profits as % of Assets	1.4%
Profits as % of Stockholder Equity	3.8%

Merck started 2019 strong, grabbing $10.8 billion in global sales during the first quarter—an 8% increase year-over-year—and raising its full-year revenue range for the year. This builds off the $42.3 billion in global sales the pharmaceutical giant netted in 2018, a 5% increase from 2017. Merck’s blockbuster cancer immunotherapy drug Keytruda continues to shine amongst its portfolio. Accounting for nearly a quarter of the company’s pharmaceutical sales, Keytruda netted $2.3 billion in sales for the first quarter in 2019. Merck is currently looking forward to the results of additional Keytruda studies later this year.

​

Company Information

CEO	Kenneth C. Frazier
Sector	Health Care
Industry	Pharmaceuticals
HQ Location	Kenilworth, N.J.
Website	https://www.merck.com
Years on Global 500 List	25
Employees	69,000

Key Financials (Last Fiscal Year)

($ Millions)	% change
Revenues ($M)	$42,294.00	5.4%
Profits ($M)	$6,220.00	159.8%
Assets ($M)	$82,637.00	-
Total Stockholder Equity ($M)	$26,701.00	-

Profit Ratios

Profit as % of Revenues	14.7%
Profits as % of Assets	7.5%
Profits as % of Stockholder Equity	23.3%

Company Information

CEO	Olivier Brandicourt
Sector	Health Care
Industry	Pharmaceuticals
HQ Location	Paris
Website	https://www.sanofi.com
Years on Global 500 List	15
Employees	104,226

Key Financials (Last Fiscal Year)

($ Millions)	% change
Revenues ($M)	$42,104.90	3.2%
Profits ($M)	$5,081.80	-46.5%
Assets ($M)	$127,339.30	-
Total Stockholder Equity ($M)	$67,295.30	-

Profit Ratios

Profit as % of Revenues	12.1%
Profits as % of Assets	4%
Profits as % of Stockholder Equity	7.6%

Company Information

CEO	Emma N. Walmsley
Sector	Health Care
Industry	Pharmaceuticals
HQ Location	Brentford, Britain
Website	https://www.gsk.com
Years on Global 500 List	25
Employees	95,490

Key Financials (Last Fiscal Year)

($ Millions)	% change
Revenues ($M)	$41,108.50	5.8%
Profits ($M)	$4,832.30	145%
Assets ($M)	$73,941.20	-
Total Stockholder Equity ($M)	$5,552.00	-

Profit Ratios

Profit as % of Revenues	11.8%
Profits as % of Assets	6.5%
Profits as % of Stockholder Equity	87%

source: fortune.com